DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation

Cancer Genomics and Proteomics

Volumn 7, Issue 1, 2010, Pages 9-16

  Fox, Brian P ^a   Kandpal, Raj P ^a  

^a Western University of Health Sciences   (United States)

Author keywords

Breast cancer invasiveness; Circulating tumor cells; DNA based assay; EPHB6; Metastasis; MSP

Indexed keywords

DNA; EPHRIN RECEPTOR B6;

ARTICLE; BLOOD VOLUME; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CONTROLLED STUDY; DNA DETERMINATION; DNA ISOLATION; DNA METHYLATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TUMOR CELL;

EID: 77949577362     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22: 4632-4642, 2004.
2. Doerfler W: On the biological significance of DNA methylation. Biochemistry 70: 505-524, 2005.
3. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007.
4. Toyota M and Issa JP: Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32: 521-530, 2005.
5. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T and Saisho H: Identification and investigation of methylated genes in hepatoma. Eur J Cancer 41: 1185-1194, 2005.
6. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P and Sukumar S: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64: 4442-4452, 2004.
7. Galm O and Herman JG: Methylation-specific polymerase chain reaction. Methods Mol Med 113: 279-291, 2005.
8. Gilbert J, Gore SD, Herman JG and Carducci MA: The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10: 4589-4596, 2004.
9. Jeronimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C, Henrique R, Teixeira MR and Lopes C: Detection of gene promoter hypermethylation in fine-needle washings from breast lesions. Clin Cancer Res 9: 3413-3417, 2003.
10. Lyko F and Brown R: DNA methyltransferase inhibitors and the development of epigenic cancer therapies. J Natl Cancer Inst 97: 1498-1506, 2005.
11. Melnick AM, Adelson K and Licht JD: The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 23: 3957-3970, 2005.
12. Schultz W: Qualified promise: DNA methylation assays for the detection and classification of human cancers. J Biomed Biotech 3: 227-229, 2005.
13. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE and Hoon DS: Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24: 4721-4727, 2005.
14. Allard WJ, Matera J, Miller MC, Repollet M, Connely MC, Rao C, Tibbe AGJ, Uhr JW and Terstappen LWMM: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
15. Pantel K, Müller V, Auer M, Nusser N, Harbeck N and Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9: 6326-6334, 2003.
16. Cristofanilli M, Budd T, Ellis MJ, Stopeck A, Matera J, Miller C, Reuben JM, Doyle GV, Allard J, Terstappen L and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Eng J Med 351: 781-791, 2004.
17. Cristofanilli M, Broglio KR, Guameri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN and Valero V: Circulating tumor cells in metastatic breast cancer: biological staging beyond tumor burden. Clin Breast Cancer 7: 417-419, 2007.
18. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM and Uhr JW: Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 95: 4589-4594, 1998.
19. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE and Sweet D: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunohistochemical and clonogenic assay techniques. Blood 82: 2605-2610, 1993.
20. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S and Kvalheim G: Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6: 103-114, 1997.
21. Hardingham JE, Kotasek D, Farmer B, Butler RN, Mi J-X, Sage RE and Dobrovic A: Immunobead-PCR: a technique for the detection for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 53: 3455-3458, 1993.
22. Zigeuner RE, Riesenberg R, Pohla H, Hofstetter A and Obernerder R: Immunomagnetic cell enrichment detects more disseminated cancer cells than immunocytochemistry in vitro. J Urol 164: 1834-1837, 2000.
23. Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H and Meye A: Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int J Cancer 92: 577-582, 2001.
24. Kagan M, Howard D, Bendle T, Mayes J, Silvia J, Repollet M, Doyle J, Allard J, Tu N, Bui T, Russell T, Rao C, Hermann M, Rutner H and Terstappen LWMM: A sample preparation and analysis for identification of circulating tumor cells. J Clin Ligand Assay 25: 104-110, 2002.
25. Wallner M, Herbst A, Behrens A, Crispin A, Stieber P, Goke B, Lamerz R and Kolligs FT: Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 12: 7347-7352, 2006.
26. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C and Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645, 2003.
27. Widschwendter A, Müller HM, Fiegl H, Ivarsson L, Wiedemair A, Müller-Holzner E, Goebel G, Marth C and Widschwendter M: DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10: 565-571, 2004.
28. Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C and Widschwendter M: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109: 163-166, 2004.
29. Laird PW: The power and promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
30. Jen J, Wu L and Sidransky D: An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann NY Acad Sci 906: 8-12, 2000.
31. Widschwendter M and Menon U: Circulating methylated DNA: A new generation of tumor markers. Clin Cancer Res 12: 7205-8, 2006.
32. Clark SJ, Harrison J, Paul CL and Frommer M: High sensitivity mapping of methylated cytosines. Nucl Acids Res 22: 2990-2997, 1994.
33. Laird PW: Cancer epigenetics. Hum Mol Genet 15: R65-76, 2005.
34. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002.
35. Himanen JP and Nikolov DB: EPH receptors and Ephrins. Int J Biochem Cell Biol 35: 130-134, 2003.
36. Nakamoto M: EPH receptors and Ephrins. Int J Biochem Cell Biol 32: 7-12, 2000.
37. Surawska H, Ma PC and Salgia R: The role of Ephrins and EPH receptors in cancer. Cytokine Growth Factor Rev 15: 419-433, 2004.
38. Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EPHA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613-618, 2003.
39. Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL, Cheung N-KV, Brodeur GM, Evans AE and Ikegaki N: Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol 35: 656-658, 2000.
40. Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM and Dcegaki N: Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36: 80-82, 2001.
41. Müller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwäble, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE and Serve H: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65: 1778-1782, 2005.
42. Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M and Vogt T: Loss of EPHB6 expression in metastatic melanoma. Int J Oncol 23: 1553-1559, 2003.
43. Fox BP and Kandpal RP: Invasiveness of breast carcinoma cells and transcript profile: EPH receptors and Ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Comm 318: 882-892, 2004.
44. Fox BP and Kandpal RP: EPHB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 28: 1706-1713, 2009.
45. Tang XX, Robinson ME, Riceberg JS, Kim DY, King B, Titus TB, Hayashi S, Flake AW, Carpentieri D and Ikegaki N: Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Caner Res 10: 5837-5844, 2004.
46. Fox BP and Kandpal RP: Transcriptional silencing of EPHB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation-specific PCR. Biochem Biophys Res Comm 340: 268-276, 2006.
47. Dottori M, Down M, Huttmann A, Fitzpatrick DR and Boyd AW: Cloning and characterization of EPHA3 (HEK) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94: 2477-2486, 1999.
48. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espin E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr and Arango D: Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-10173, 2005.
49. Davalos V, Dopeso H, Castano J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espin E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz S Jr and Arango D: EPHB4 and survival of colorectal cancer patients. Cancer Res 66: 8943-8948, 2006.
50. Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, Tanaka M, Kanamori M, Nakamura T, Shinmura K and Sugimura H: Down-regulation of EPHA7 by hypermethylation in colorectal cancer. Oncogene 24: 5637-5647, 2005.
51. Thompson EW, Paik S, Brunner N, Sommers, CL, Zugmaier G, Clarke R, Shima TB, Torri, J, Donahue S and Lippman ME: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
52. Lee CW and Jordan RE: The complement system in bullous pemphigoid: VII. Fixation of the regulatory protein β1H globulin by pemphigoid antibody. J Invest Dermatol 80: 465-469, 1980.
53. Serrano MJ, Sánchez-Rovira P, Delgado-Rodriguez M and Gaforio JJ: Detection of circulating tumor cells in the context of treatment: Prognostic value in breast cancer. Cancer Biol Ther 8: 671-675, 2009.
54. Ring A, Smith IE and Dowsett M: Circulating tumour cells in breast cancer. Lancet Oncol 5: 79-88, 2004.
55. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocrine-Related Cancer 13: 1033-1067, 2006.
56. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC and Lingle WL: Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 11: 3722-3732, 2005.